Overall, the sessions were well attended and a lot of questions were asked. Two-thirds of the speakers were from industry and the rest from academia. Of particular note, The academics presented cutting-edge science in the antibody discovery and development area. Business representatives from various therapeutic antibody companies discussed in detail various aspects and challenges of building a viable therapeutic antibody company.